Wire · opportunities
AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
AL-S Pharma announced new Phase 2 clinical trial data for AP-101 showing greater body-weight preservation in ALS patients compared to placebo, reinforcing weight as a surrogate marker of disease progression. The company plans to initiate a confirmatory Phase 3 trial in 2027 to evaluate AP-101's safety and efficacy in ALS.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new opportunity to engage with a confirmatory ALS treatment trial focusing on weight preservation as a key clinical marker. This could redefine your approach to ALS therapeutic development and patient outcomes measurement.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics